<DOC>
	<DOCNO>NCT02211924</DOCNO>
	<brief_summary>Study investigate safety , tolerability , pharmacokinetics pharmacodynamics BI 44847 Japanese healthy volunteer</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Rising Oral Doses BI 44847 Administered Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects healthy male volunteer meet criterion : Persons without clinically remarkable finding clinically evident complication base concurrent illness , past medical history , physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , laboratory test result Persons 20 old 35 young Persons BMI 18.5 kg/m2 25.0 kg/m2 less Persons willing participate trial study initiation give write consent accordance Good Clinical Practice Any find medical examination ( include BP , Pulse Rate ( PR ) ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug within 10 day prior administration trial Participation another trial investigational drug within four month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL ) within four week prior administration trial Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre 19 . A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) The use concomitant medication prolong QT/QTc interval Any ECG value outside reference range clinical relevance include , limited QRS interval &gt; 120 m Elevated urinary glucose level screen ( &gt; 15 mg/dl )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>